

AGENDA

- 09.00-09.30 General Assembly & Coordinator address
Claudia Monaco - Kennedy Institute, University of Oxford, UK
- WP-LEADER LED SYMPOSIUM (introduced and chaired by each WP leader)
- 09.30-10.20 WP1 Discovery of B cell specific therapeutic targets for CVD
Francois Mach - Université de Geneve, SWITZERLAND (WP leader)
Imo Hoefler - Universitair Medisch Centrum Utrecht, THE NETHERLANDS
- 10.20-10.50 *Coffee break*
- 10.50-11.40 WP2 Target selection
Ignat Drozdov - Bering LTD, UK (WP leader)
Harry Björkbacka - Lunds Universitet, SWEDEN
- 11.40-12.45 WP3 Validation of novel targets for B cell responses with pro-atherogenic outcomes
Marie Wickström Lindholm - Santaris Pharma A/S, DENMARK (WP leader)
Alessio Nencioni - Università degli Studi di Genova, ITALY
Angelique Heckman - genOway, FRANCE
- 12.45-14.15 *Lunch*
- 14.15-15.05 WP4 Validation of targets related to the enhancement of Bregs as a novel therapeutic strategy
Claudia Mauri - University College of London, UK (WP leader)
Jennifer Cole - Kennedy Institute, University of Oxford, UK
Stephen Malin - Karolinska Institutet, Sweden
- 15.05-15.25 WP5&6
Riccardo Bertini - ALTA Ricerca e Sviluppo in Biotecnologie, ITALY
- 15.25-16.00 *Coffee break*
- 16.00 AtheroBcell Steering Committee meeting